Portola Pharmaceuticals, Inc. (PTLA) CEO Sells $14,927,243.57 in Stock
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) CEO William Lis sold 269,299 shares of the stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $55.43, for a total value of $14,927,243.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
William Lis also recently made the following trade(s):
- On Tuesday, April 11th, William Lis sold 6,750 shares of Portola Pharmaceuticals stock. The shares were sold at an average price of $36.06, for a total value of $243,405.00.
Portola Pharmaceuticals, Inc. (PTLA) traded up 1.80% during mid-day trading on Thursday, hitting $56.42. 1,307,272 shares of the company were exchanged. The company’s market capitalization is $3.22 billion. Portola Pharmaceuticals, Inc. has a 12-month low of $15.68 and a 12-month high of $60.00. The company’s 50-day moving average is $40.65 and its 200 day moving average is $34.25. Portola Pharmaceuticals also saw unusually large options trading activity on Monday. Stock investors bought 7,796 call options on the company. This represents an increase of approximately 309% compared to the average volume of 1,907 call options.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.46. The company had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.21 million. Portola Pharmaceuticals had a negative net margin of 759.21% and a negative return on equity of 106.68%. Portola Pharmaceuticals’s revenue was down 37.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.15) earnings per share. Analysts expect that Portola Pharmaceuticals, Inc. will post ($4.30) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/06/29/portola-pharmaceuticals-inc-ptla-ceo-sells-14927243-57-in-stock.html.
PTLA has been the topic of a number of analyst reports. Oppenheimer Holdings, Inc. set a $46.00 price target on Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 9th. Citigroup Inc. set a $51.00 price target on Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, April 19th. Vetr downgraded Portola Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $45.18 price target on the stock. in a research note on Monday, March 20th. Cowen and Company increased their price target on Portola Pharmaceuticals from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, March 20th. Finally, Morgan Stanley increased their price target on Portola Pharmaceuticals from $31.00 to $47.00 and gave the company an “overweight” rating in a research note on Monday, March 6th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Portola Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $55.40.
Several institutional investors have recently modified their holdings of PTLA. BlackRock Inc. raised its position in shares of Portola Pharmaceuticals by 68,964.1% in the first quarter. BlackRock Inc. now owns 4,034,725 shares of the biopharmaceutical company’s stock worth $158,121,000 after buying an additional 4,028,883 shares during the period. Norges Bank purchased a new position in Portola Pharmaceuticals during the fourth quarter valued at about $10,046,000. Bogle Investment Management L P DE purchased a new position in Portola Pharmaceuticals during the first quarter valued at about $12,945,000. FMR LLC raised its position in Portola Pharmaceuticals by 5.6% in the first quarter. FMR LLC now owns 3,902,000 shares of the biopharmaceutical company’s stock valued at $152,919,000 after buying an additional 205,751 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Portola Pharmaceuticals by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,614,814 shares of the biopharmaceutical company’s stock valued at $180,855,000 after buying an additional 192,420 shares during the last quarter. Institutional investors own 85.24% of the company’s stock.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.